Vysis FISH
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $40,680 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $40,680 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A retrospective study to evaluate the reproductibility of the Vysis EGFR CDx Fluorescence in-situ Hybridization (FISH) Kit assay on formalin-fixed paraffin-embedded glioblastoma multiforme (GBM) specimens including the near cut-off specimens (the Protocol) | Abbott Laboratories | $40,680 | 0 |
Top Doctors Receiving Payments for Vysis FISH
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Grand Rapids, MI | $40,680 | 1 |
Manufacturing Companies
- Abbott Laboratories $40,680
Product Information
- Type Device
- Total Payments $40,680
- Total Doctors 0
- Transactions 1
About Vysis FISH
Vysis FISH is a device associated with $40,680 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2018 to 2018. In 2018, $40,680 was paid across 1 transactions to 0 doctors.
The most common payment nature for Vysis FISH is "Unspecified" ($40,680, 100.0% of total).
Vysis FISH is associated with 1 research study, including "A retrospective study to evaluate the reproductibility of the Vysis EGFR CDx Fluorescence in-situ Hybridization (FISH) Kit assay on formalin-fixed paraffin-embedded glioblastoma multiforme (GBM) specimens including the near cut-off specimens (the Protocol)" ($40,680).